vancomycin mylan
mylan s.a.s. - vankomicinas - milteliai infuzinio tirpalo koncentratui - 1000 mg; 500 mg - vancomycin
docetaxel mylan
mylan s.a.s. - docetakselis - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antinavikiniai vaistai - krūties vėžio gydymas, specialios plaučių vėžio formos (nesmulkialąstelinis plaučių vėžys), prostatos vėžys, skrandžio vėžys arba galvos ir kaklo vėžys.
bimatoprost/timolol mylan
mylan pharmaceuticals limited - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations
ivabradine mylan
mylan pharmaceuticals limited - ivabradinas - plėvele dengtos tabletės - 7,5 mg; 5 mg - ivabradine
travoprost/timolol mylan
mylan pharmaceuticals limited - travoprostas/timololis - akių lašai (tirpalas) - 40 µg/5 mg/ml - timolol, combinations
agomelatine mylan
mylan pharmaceuticals limited - agomelatinas - plėvele dengtos tabletės - 25 mg - agomelatine
alendronic acid/colecalciferol mylan
mylan pharmaceuticals limited - alendrono rūgštis/kolekalciferolis - tabletės - 70 mg/2800 tv - alendronic acid and colecalciferol
alendronic acid/colecalciferol mylan
mylan pharmaceuticals limited - alendrono rūgštis/kolekalciferolis - tabletės - 70 mg/5600 tv - alendronic acid and colecalciferol
pirfenidone viatris
viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresantai - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).
dapagliflozin viatris
viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - narkotikai, vartojami diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ir 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.